(Q43770759)

English

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Brian H Kushner

1

object named as

Kushner BH

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Nai-Kong V Cheung

2

object named as

Cheung NK

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3

object named as

Kramer K

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Calleja E

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Boulad F

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

0 references

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

551-556

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

A phase II evaluation of thiotepa in pediatric central nervous system malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

High-dose chemotherapy regimens for solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

21 January 2018

Myeloablative combination chemotherapy without total body irradiation for neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703213

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703213

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43770759&oldid=2206249241"